RPTP Share Price

Open 8.95 Change Price %
High 9.05 1 Day 0.00 0.00
Low 8.95 1 Week 0.00 0.00
Close 9.00 1 Month 0.00 0.00
Volume 753206 1 Year 3.79 72.74
52 Week High 9.05
52 Week Low 4.93
RPTP Important Levels
Resistance 2 9.09
Resistance 1 9.05
Pivot 9.00
Support 1 8.95
Support 2 8.91
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
DCTH 0.16 -33.33%
FTR 1.22 8.93%
FTR 1.22 8.93%
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
More..
NASDAQ USA Top Gainers Stocks
OPXAW 0.12 200.00%
AVEO 1.25 71.23%
LOCM 0.09 50.00%
MYRX 0.09 50.00%
SNCR 16.24 33.33%
QUIK 1.60 31.15%
WRES 0.09 28.57%
IIN 8.35 27.48%
IIN 8.35 27.48%
IIN 8.35 27.48%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
TOPS 0.80 -66.67%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Raptor Pharmaceutical Corp. (NASDAQ: RPTP)

RPTP Technical Analysis 5
As on 24th Oct 2016 RPTP Share Price closed @ 9.00 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 5.71 & Strong Buy for SHORT-TERM with Stoploss of 8.17 we also expect STOCK to react on Following IMPORTANT LEVELS.
RPTP Target for June
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
RPTP Other Details
Segment EQ
Market Capital 225990480.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.raptorpharma.com
RPTP Address
RPTP
5 Hamilton Landing
Suite 160
Novato, CA 94949
United States
Phone: 415-408-6200
Fax: 415-382-8002
RPTP Latest News
Interactive Technical Analysis Chart Raptor Pharmaceutical Corp. ( RPTP NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Raptor Pharmaceutical Corp.
RPTP Business Profile
Raptor Pharmaceuticals Corp. (RPC), formerly TorreyPines Therapeutics, Inc., is an early development-stage Company. The Company�s product portfolio includes both candidates from its drug targeting platforms and in-licensed and acquired product candidates. As of August 31, 2010, its pipeline includes three clinical development programs. It also has three other clinical-stage product candidates, for which it is seeking business development partners, and it has four preclinical product candidates it is developing, three of which are based upon its drug-targeting platforms. As of August 31, 2010, the Company had no revenues. On September 29, 2009, the Company and its wholly owned subsidiary, ECP Acquisition, Inc., completed a reverse merger, business combination with RPC, pursuant to which RPC became its wholly owned subsidiary.